Peter Taylor, EULAR 2021: Coadministration of Filgotinib and Statins in Rheumatoid Arthritis
We were delighted to speak with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) around the safety of statin and filgotinib coadministration in patients with rheumatoid arthritis across the DARWIN and FINCH clinical trials.
The abstract ‘CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS‘ (POS0660), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- What is the role of statins in the management of rheumatoid arthritis, and how prevalent is their use? (0:11)
- What are the potential risks of coadministration of JAK inhibitors such as filgotinib and statins? (1:04)
- Could you tell us a little about the design and inclusion criteria of your study assessing coadministration of filgotinib and statins? (1:48)
- What were the findings of this study, and what are their implications for clinical practice? (3:22)
- What other evidence supports these findings? (5:17)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB
Support:Â Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
